Centene Agrees to $215 Million Settlement With California for Alleged Medicaid Overbilling
The nation鈥檚 largest Medicaid insurer denies wrongdoing after the California attorney general鈥檚 office investigated it for inflating prescription drug costs.
The independent source for health policy research, polling, and news.
301 - 320 of 1,300 Results
The nation鈥檚 largest Medicaid insurer denies wrongdoing after the California attorney general鈥檚 office investigated it for inflating prescription drug costs.
As he takes the reins of the Senate Health, Education, Labor & Pensions Committee, the independent from Vermont and implacable champion of 鈥淢edicare for All鈥 maps out his strategy for negotiating with Republicans 鈥 and Big Pharma.
The online women鈥檚 pharmacy agreed to pay $15 million to the state Department of Justice and $3.3 million to the Department of Insurance over claims it overbilled Medi-Cal.
Pharmacy closures by two of the biggest home infusion companies point to grave shortages and dangers for patients who require IV nutrition to survive.
The Vaccines for Children program, which buys more than half the pediatric vaccines in the U.S., may not cover the RSV shot for babies because it鈥檚 not technically a vaccine.
Private equity groups are cashing in on rising rates of alcohol and drug addiction in the U.S. But they aren鈥檛 necessarily investing in centers with the best treatment standards, and they often cut extra services.
In Part II of this special two-part episode, Alice Miranda Ollstein of Politico, Sandhya Raman of CQ Roll Call, and Sarah Varney of KHN join KHN chief Washington correspondent Julie Rovner to discuss how the abortion debate has evolved since the Supreme Court overturned the nationwide right to abortion in 2022, and what might be the flashpoints for 2023. Also, for extra credit, the panelists recommend their most memorable reproductive health stories from the last year.
Supporters of a proposed law say it would fill a health provider gap in rural areas, while doctors worry it will give pharmacists power outside the scope of their education.
A single booster seems to prevent death and hospitalization in most people, but protection from the current vaccines wanes within months. FDA experts say they need to know more from the Centers for Disease Control and Prevention to decide the best long-term strategy.
In Part I of this special two-part episode, Alice Miranda Ollstein of Politico, Sandhya Raman of CQ Roll Call, and Sarah Varney of KHN join KHN chief Washington correspondent Julie Rovner to discuss how the abortion debate has evolved since the Supreme Court overturned the nationwide right to abortion in 2022, and what might be the flashpoints for 2023. Also in this episode, Rovner interviews Elizabeth Nash of the Guttmacher Institute, about changing reproductive policies in the states.
Covid-19 continues to hit seniors with disproportionate severity. Experts say Paxlovid is an effective therapy that is being underprescribed for people 65 and older.
This year鈥檚 JPMorgan confab, the first since covid鈥檚 chilling effect on such gatherings, was full of energy and enthusiasm. But it was also marked by questions about the future of health care investment.
California Attorney General Rob Bonta is taking three major drugmakers and three distributors to court, alleging the companies illegally raised prices at the expense of diabetes patients.
Leaders of the new Republican-led U.S. House kicked off their legislative agenda with two bills supported by anti-abortion groups. While neither is likely to become law, the move demonstrates how abortion will continue to be an issue in Washington. Meanwhile, as open enrollment for the Affordable Care Act nears its end in most states, the number of Americans covered by the plans hits a new high. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico, and Sarah Karlin-Smith of the Pink Sheet join KHN鈥檚 Julie Rovner to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
As flexible treatment options spurred by the covid pandemic wane, patients relying on medications classified as controlled substances worry that without action to extend the loosened rules, it鈥檒l be harder to get their meds.
This strategy 鈥 now in place in at least 10 states 鈥 is part of an effort to curb accidental opioid overdose deaths by patients who take these powerful medications.
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here鈥檚 a collection of their appearances.
While supporters cheer the PASTEUR Act as an essential strategy to stem the rise of antibiotic-resistant pathogens, critics call it a multibillion-dollar giveaway to Big Pharma.
KHN gives readers a chance to comment on a recent batch of stories.
Top negotiators in Congress have agreed to a framework for government spending into next year, but there are details to iron out before a vote 鈥 such as the scheduled Medicare payment cuts that have providers worried. Also, the Biden administration reopens its program allowing Americans to request free covid-19 home tests, as hopes for pandemic preparedness measures from Congress dim. Rachel Cohrs of Stat, Alice Miranda Ollstein of Politico, and Rebecca Adams of KHN join KHN鈥檚 Mary Agnes Carey to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
漏 2026 KFF